About this trial
A new algorithm derived from only patient age and components of the complete blood count and basic metabolic panel can identify patients discharged from the hospital who may benefit from a blood thinner (called rivaroxaban) to decrease their risk of blood clots, and for whom the risk of bleeding is minimal.
The purpose of this study is to evaluate the use of a pop-up alert, which will be seen by clinicians when a discharging patient has been identified as being someone for whom the risk of blood clots is high, but for whom bleeding risk is estimated to be low.
The pop-up alert will be enabled in a sequential fashion for each group of hospitals in 1 month blocks. We will look to see if the pop-up alert changes the number of patients who receive rivaroxaban. We will also measure the outcomes of blood clots and bleeding among all discharging patients.
Eligibility criteria
Qualifiers
Physician, nurse practitioner, or physician assistant hospitalist
Physician internal medicine
Physician family medicine
Patient age ≥ 18 years.
Disqualifiers
Pregnant during encounter
Discharge order completed by ineligible clinician type
Apixaban
Dabigatran
Trial design
Treatments tested in this trial
- EHR (electronic health record) alert
- No EHR (electronic health record) alert
Treatment groups
Sponsors and collaborators
Scott C. Woller, MD
Lead sponsor
Intermountain Health Care, Inc.
Sponsor institution
Janssen Pharmaceuticals
Collaborator